First AD

Second AD

EMERALD-1 Study: Outshining Negative Clinical Trials Based Upon TKI- and Liver-directed Therapies

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Gastrointestinal Cancer

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Hepatocellular Carcinoma

Evolving Treatments in Hepatocellular Carcinoma: Updates from ASCO GI 2024

Peer Exchange

Drs Gong and Covey emphasize the impact of TACE + durvalumab ± bevacizumab combination therapy surrounding HCC treatment strategy.

Hepatocellular Carcinoma (HCC) Disease State Overview

Utilizing Interventional Radiology and Liver-directed Therapies

Determining Transarterial Chemoembolization (TACE) Candidacy for Patients with HCC

EMERALD-1 Study: Significance as Presented at ASCO GI 2024

IMBrave-050 Study Overview

Patient Profile 1: Advanced HCC Treated with Durvalumab and Tremelimumab 

HIMALAYA Study in Advanced Stage HCC 

Establishing Optimal HCC Treatment Strategy

IMBrave150 Study Overview

HCC Treatment Strategy Driven by Real-World Evidence 

Combining Liver-directed and Systemic Therapies in HCC

Patient Profile 2: Patient Progression After Frontline HCC Therapy 

CARES-310 Trial: Impressions and Clinical Impact on HCC Treatment Landscape 

REGONEXT Study: Driving Second-line HCC Treatment Strategy 

Trajectory of Evolving HCC Treatment Landscape 